Brown Advisory Inc. Cuts Stock Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

Brown Advisory Inc. decreased its holdings in OrthoPediatrics Corp. (NASDAQ:KIDS) by 4.0% in the 4th quarter, HoldingsChannel reports. The firm owned 1,534,028 shares of the company’s stock after selling 63,375 shares during the quarter. Brown Advisory Inc. owned approximately 0.06% of OrthoPediatrics worth $35,559,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in KIDS. R Squared Ltd acquired a new stake in OrthoPediatrics in the 4th quarter valued at about $48,000. KLP Kapitalforvaltning AS acquired a new stake in OrthoPediatrics in the fourth quarter valued at approximately $79,000. AlphaCentric Advisors LLC purchased a new position in OrthoPediatrics in the fourth quarter worth approximately $171,000. Wells Fargo & Company MN grew its holdings in OrthoPediatrics by 31.1% during the 4th quarter. Wells Fargo & Company MN now owns 9,853 shares of the company’s stock worth $228,000 after acquiring an additional 2,338 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in shares of OrthoPediatrics in the 4th quarter valued at approximately $268,000. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Trading Down 1.5 %

Shares of OrthoPediatrics stock opened at $21.08 on Tuesday. The firm has a market cap of $511.97 million, a price-to-earnings ratio of -17.14 and a beta of 1.09. OrthoPediatrics Corp. has a 52-week low of $20.25 and a 52-week high of $35.99. The company’s 50-day simple moving average is $23.14 and its 200-day simple moving average is $24.18. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. The company had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same quarter in the previous year, the firm posted ($0.23) EPS. As a group, equities research analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on KIDS. Needham & Company LLC reiterated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a research note on Wednesday, April 9th. Stifel Nicolaus dropped their price objective on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Lake Street Capital assumed coverage on OrthoPediatrics in a research report on Monday, April 7th. They set a “buy” rating and a $37.00 target price on the stock. Finally, Truist Financial reduced their price objective on shares of OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating for the company in a research report on Friday, April 11th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, OrthoPediatrics presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.00.

Insiders Place Their Bets

In other news, CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the sale, the chief executive officer now directly owns 319,155 shares in the company, valued at approximately $7,934,193.30. This trade represents a 2.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gregory A. Odle sold 5,359 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $133,224.74. Following the sale, the insider now directly owns 148,788 shares in the company, valued at $3,698,869.68. This trade represents a 3.48 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,732 shares of company stock worth $589,978. 32.70% of the stock is owned by corporate insiders.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.